$THLD new volume recovery $1.21 Website

New Post Public Reply Private Reply Replies (1) Message Board
PoemStone
$THLD new volume recovery $1.21

Website
threshold.png


Shares Outstanding 71.51M
Float 65.4M

% Held by Insiders 10.38%
% Held by Institutions 1 52.40%
Shares Short 292.39k
Short Ratio 0.49
Short % of Float 0.44%
Shares Short (prior month) 413.1k

Headlines
and Filings

Threshold Pharmaceuticals, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and advanced pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma; and Phase I/II clinical trials for multiple myeloma. The company is also involved in the study of evofosfamide in investigator sponsored trials, including Phase I/II clinical trials for glioblastoma; Phase I clinical trials for advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; Phase I clinical trials for advanced solid tumors; and Phase I/II clinical trials for advanced kidney cancer or liver cancer. In addition, it engages in developing Tarloxotinib, an investigational hypoxia-activated EGFR tyrosine kinase inhibitor, which is in two Phase II clinical trials for patients with advanced non-squamous non-small cell lung cancer, as well as patients with squamous cell carcinomas of the head, neck, or skin; and [18F]-HX4, an investigational PET imaging agent for hypoxia. The company has a license and co-development agreement with Merck KGaA to co-develop and commercialize evofosfamide; license agreement with Auckland UniServices Ltd. for the development program based on Tarloxotinib; and license agreement with Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DCM Services Teams with AKUVO to Boost Estate Recoveries

Updated Category News Views 13

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Continue Reading
NYSE Reflects on 9/11: Honoring Lives and Legacy

Updated Category News Views 6

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

Continue Reading
Americas Cardroom's Poker Series Hits $7.2M Haul

Updated Category News Views 5

Massive Prize Pools Emerge in Just Four Days I found myself eyeballing some jaw-dropping numbers from Americas Cardroom's latest poker series, the Online Super Series XL. It's not every day you see nearly a hundred tournaments rake in over $7.2 million in prize pools in just four days. From September 6th to 9th, a whopping 62,847 entries signed up to make an honest...

Continue Reading
Lick the Plate Hits 2,000 Shows with Clown Band

Updated Category News Views 5

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

Continue Reading
Jari Spirits Set to Shake Up U.S. Market After Big Wins

Updated Category News Views 4

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

Continue Reading
Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 5

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading
Fermi's Founder Pushes for Board Overhaul: What's Next?

Updated Category News Views 4

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

Continue Reading
Melissa Rivers Brings Her Wit Back to Emmys Carpet

Updated Category News Views 11

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Continue Reading
Modeling and Mental Health Join Forces for Wellness

Updated Category News Views 3

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Continue Reading
Oil Markets Shift Focus: Pipelines Trump Drilling

Updated Category News Views 6

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Continue Reading

Top 5 Most Recently Viewed Articles

SaverOne Adjusts Share Ratio to Align with Nasdaq Standards

Updated Category News Views 267

SaverOne Adjusts Share Ratio to Align with Nasdaq Standards SaverOne 2014 Ltd. (NASDAQ: SVRE) has recently implemented a significant adjustment to its share ratio to meet compliance with the Nasdaq's strict listing requirements. This strategic move comes after the company faced challenges due to its stock price breaching the minimum bid price set by Nasdaq. Navigating...

Continue Reading
BridgeBio Announces Upcoming Investor Engagements for Growth

Updated Category News Views 244

BridgeBio Pharma's Participation in Investor Conferences BridgeBio Pharma, Inc. (NASDAQ: BBIO) is set to actively engage with investors in November, taking part in prominent healthcare investor conferences. These events represent a significant opportunity for the company to share its advancements in treating genetic diseases and connect with stakeholders in the healthcare...

Continue Reading
Tesla's Earnings Report: A Critical Moment for Investors

Updated Category News Views 155

An Overview of Tesla's Market Position Shares of Tesla Inc. are approaching their next earnings report amid increasing tension and scrutiny. Following a seven-day losing streak at the close of 2025, the stock has been trying to stabilize at its rising support line. This price action indicates a potential higher low in the ongoing rally since last summer, which could be...

Continue Reading
Rumble Prepares for Third Quarter Earnings Announcement

Updated Category News Views 218

Rumble's Upcoming Third Quarter Earnings Release Rumble Inc. (NASDAQ: RUM) is gearing up for an important financial milestone by announcing the release of its earnings report for the fiscal quarter that ended recently. This event is scheduled to take place after the market closes on a Tuesday in the near future. The company has positioned itself as a significant player in...

Continue Reading
Investigation Launched for Fly-E Group, Inc. Investors

Updated Category News Views 184

Investigation Initiated for Fly-E Group, Inc. Investors Glancy Prongay & Murray LLP, a renowned national shareholder rights law firm, has announced an investigation on behalf of Fly-E Group, Inc. (FLYE) investors. This inquiry centers around potential violations of federal securities laws by the company. Notable Recent Events Affecting Fly-E Recently, Fly-E faced serious...

Continue Reading